Adolor

About Adolor

Adolor Corporation (NASDAQ:ADLR) is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The Company's first product, ENTEREG® (alvimopan) was approved by the FDA and launched with Glaxo Group Limited in mid-2008. ENTEREG is indicated to accelerate the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. For more information on ENTEREG, including its full prescribing information, visit www.ENTEREG.com.

The Company’s research and development pipeline includes: two novel delta opioid receptor agonists, currently in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; a peripheral mu opioid receptor antagonist entering development for chronic opioid bowel dysfunction (OBD); and several opioid and non-opioid discovery programs.

Adolor is:
-Committed to innovation, focused on invention
-Driven by imagination to meet unmet medical needs in pain management

Website	http://www.adolor.com
Employees	11-50 employees View all Adolor employees
Industry	Pharmaceutical Manufacturing
Headquarter	US
Founded	1993